Lupin announces launch of ‘Sildenafil' in the United States; stock zooms ~3%

30 Sep 2022 , 09:23 AM

Lupin Limited announced the introduction of Sildenafil for Oral Suspension, 10 mg/mL, which has been approved by the US Food and Drug Administration (FDA).

Sildenafil for Oral Suspension, 10 mg/mL is the generic equivalent of Viatris Specialty LLC’s Revatio for Oral Suspension, 10 mg/mL, said the company on Thursday.

In the United States, yearly sales of Sildenafil for Oral Suspension (RLD Revatio) were anticipated to be USD 64 million (IQVIA MAT July 2022).

Lupin is a market leader in the cardiovascular, anti-diabetic, and respiratory sectors, as well as in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women’s health segments.

At around 9.25 AM, Lupin was trading at Rs671.90 up by 2.74% from its previous closing of Rs654 on the BSE. The scrip opened at Rs660 and touched intraday high and low of Rs672.95 and Rs660 respectively.

For feedback and suggestions, write to us at [e-mail]